StockData
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) shareholders

ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.84−0.03 (-3.91%)

Close on Nov 17, 2026Market cap $13.38MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
8.1%
1M of 16M shares
Institutional holders
20
8 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
John M. Fife8,999,800–13G (passive)Aug 19, 2024
Olmsted Investments LLC10,00028.60%13G (passive)Aug 19, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ALLRValueChange% of portfolio
Renaissance Technologies LLC331,5092.08%$427.65K+103,4250.00%
Vanguard Capital Management LLC171,7951.08%$221.62K–0.00%
Geode Capital Management, LLC154,8670.97%$199.78K−35,5260.00%
State Street Corp137,6000.86%$177.50K–0.00%
Militia Capital Management LLC98,9780.62%$127.68KNew0.00%
Citadel Advisors LLC91,7480.58%$118.36KNew0.00%
Vanguard Fiduciary Trust Co74,9130.47%$96.64K–0.00%
Hrt Financial LP37,0030.23%$47.00KNew0.00%
Northern Trust Corp36,5340.23%$47.13K−11,5690.00%
Jane Street Group, LLC36,0210.23%$46.47KNew0.00%
Two Sigma Investments, LP27,4920.17%$35.47K–0.00%
UBS Group AG26,5890.17%$34.30K+3,4310.00%
XTX Topco Ltd20,8840.13%$26.94K−8,0830.00%
Susquehanna International Group, Llp17,2210.11%$22.22KNew0.00%
Virtu Financial LLC15,3220.10%$20.00KNew0.00%
Tower Research Capital LLC (TRC)2,6500.02%$3.42KNew0.00%
Caitong International Asset Management Co., Ltd220.00%$28+210.00%
FMR LLC130.00%$17New0.00%
Danske Bank A/S10.00%$1–0.00%
Jones Financial Companies Lllp10.00%$1–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026201M8.1%8 / 33 / 20M0M
Q1 2026141M6.0%5 / 24 / 60M0M
Q4 2025161M8.1%6 / 43 / 11M0M
Q3 2025111M6.5%7 / 11 / 61M0M
Q2 2025100M1.2%4 / 31 / 30M0M
Q1 202590M0.6%6 / 20 / 30M0M
Q4 202460M0.7%3 / 21 / 10M0M
Q3 202440M0.1%4 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held ALLR in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ALLRValue% of fundAs of
Vanguard Extended Market Index Fund171,7951.08%$221.62K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund94,2890.59%$154.63K0.00%May 31, 2026
Fidelity Total Market Index Fund22,1660.14%$36.35K0.00%May 31, 2026
Fidelity Series Total Market Index Fund21,5950.14%$35.42K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jeremy R. GraffSee Remarks80,0950.50%Oct 9, 2026
Thomas JensenCEO596,7343.75%May 14, 2026
Jeffrey S. ErvinCFO150,0000.94%Apr 30, 2026
Alexander EpshinskyCFO85,0510.53%Jan 24, 2025
Jesper HoeilandDirector25,0000.16%May 11, 2026
Gerald W. McLaughlinDirector70,0000.44%May 7, 2026
Laura BenjaminDirector––Jan 24, 2025
Joseph Walter VazzanoDirector––Jan 24, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jeremy R. Graff
See Remarks
Sep 30, 2026Tax withholding−14,613$0.97$14.17K80,095
Jeremy R. Graff
See Remarks
Sep 30, 2026Option exercise+39,494––94,708
Thomas Jensen
CEO
Jan 28, 2026Award+200,000––596,734
Gerald W. McLaughlin
Director
Jan 28, 2026Award+45,000––70,000
Jeffrey S. Ervin
CFO
Jan 28, 2026Award+150,000––150,000
Jeremy R. Graff
See Remarks
Jan 28, 2026Award+133,333––381,644
Jeremy R. Graff
See Remarks
Jan 22, 2026Tax withholding−17,814$1.18$21.02K55,214
Jeremy R. Graff
See Remarks
Jan 22, 2026Option exercise+48,147––73,028
Jesper Hoeiland
Director
Jan 7, 2026Award+25,000––25,000
Jeremy R. Graff
See Remarks
Jan 7, 2026Award+133,333––381,644
Jeremy R. Graff
See Remarks
Sep 30, 2025Tax withholding−14,613$1.58$23.09K24,881
Jeremy R. Graff
See Remarks
Sep 30, 2025Option exercise+39,494––39,494
Jeremy R. Graff
CDO
Jan 22, 2025Award+144,441––262,924
Alexander Epshinsky
CFO
Jan 22, 2025Award+29,496––85,051
Thomas Jensen
CEO
Jan 22, 2025Award+396,734––396,734
Jeremy R. Graff
See Remarks
Sep 30, 2024Award+118,483$2.11$250.00K118,483

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.55%
0M shares short
Days to cover
1.9
At 0M shares a day
Change since last report
+37.3%
From 0M shares
Short volume, 20 days
34.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Allarity Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,900 shares on Oct 13, 2026 over the last 90 days.

See a number that looks wrong?